Skip to main content

Table 3 Baseline demographic and clinical characteristics of HF and non-HF patients from validation group

From: Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure

Characteristics HF patients (n = 7) Non-HF patients (n = 7) P value
Men 7 (100%) 7 (100%) NA
Women 0 (0%) 0 (0%) NA
Age (years) 59.7 ± 9.4 56.7 ± 13.2 0.634
BMI (kg/m2) 30 ± 3.7 26.1 ± 4.2 0.092
Hypertension 5 (71.4%) 5 (71.4%) 1
Diabetes 2 (28.6%) 0 (0%) 0.462
Previous MI 0 (0%) 0 (0%) NA
Smoking 3 (42.9%) 5 (71.4%) 0.592
Hypercholesterolemia 5 (71.4%) 5 (71.4%) 1
AMI 3 (42.9%) 2 (28.6%) 1
NT-proBNP (pg/mL)a 1,960.9 ± 3,421.9 119.4 ± 118.9 0.002
LVEF (%)a 28.9 ± 6.3 57.7 ± 4.7 <0.001
Medications
Aspirin 7 (100%) 7 (100%) NA
Clopidogrel 7 (100%) 7 (100%) NA
Beta blockers 7 (100%) 6 (85.7%) 1
ACE inhibitors 7 (100%) 7 (100%) NA
Statins 7 (100%) 7 (100%) NA
Diuretics 5 (71.4%) 1 (14.3%) 0.103
  1. aNT-proBNP, LVEF measured 6 months after AMI.
  2. Data are presented as mean value ± standard deviation or number or percentage of patients. P value <0.05 was considered significant.
  3. ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.